Platelet-rich plasma (PRP) a biogenic stimulator in treatment of primary atrophic rhinitis

Abstract

Background: Primary atrophic rhinitis (1ry AR) is a chronic nasal disease characterized by the loss of mucociliary clearance and presence of viscid secretions and dried crusts that causes a characteristic foul odor, usually bilateral. A large range of treatment modalities had been tried, yet there is still no agreement upon a curative treatment with long-lasting success. The purpose of the study was to assess the value of platelet-rich plasma as a biogenic stimulator for healing acceleration in primary atrophic rhinitis. A total of 78 cases clinically diagnosed to have primary atrophic rhinitis were included. Nasal endoscopy, Sino-Nasal Outcome Test-25 questionnaire, mucociliary clearance assessment by saccharine transit time test, and biopsy specimens were achieved before 1 month and 6 months after the application of platelet-rich plasma in group A (cases) and platelet-poor plasma in group B (controls). Results: All patients in group A showed endoscopic improvement and reduction in the incidence of the most frequently encountered symptoms before platelet-rich plasma injection including nasal crusts, 36 (92.30%); foetor, 31 (79.48%); nasal obstruction, 30 (76.92%); anosmia, 17 (43.58%); and epistaxis, 7 (17.94%) to nasal crusts, 9 (23.07%); foetor, 13 (33.33%); nasal obstruction, 14 (35.89%); anosmia, 13 (33.33%); and epistaxis, 3 (7.69%), 6 months after, and this was reflected in the reduction of the Sino-Nasal Outcome Test-25 scores which was averaged 40 before platelet-rich plasma to 9, 6 months after. Similarly, the mucociliary clearance time was significantly reduced after platelet-rich plasma injection; saccharine transit time test was initially averaged at 1980 s and got reduced to 920 s, 6 months after platelet-rich plasma injection. Conclusion: The use of platelet-rich plasma as a biogenic stimulator is a possible innovative less invasive approach that can be effective in repairing tissue dystrophy through further future studies.